Tag: AstraZeneca

February 19, 2016 Off

AstraZeneca’s Brilique OK for marketing in EU

By Dino Mustafić

The European Commission has granted to AstraZeneca marketing authorisation for Brilique (ticagrelor) at a new 60mg dose for the treatment of patients who have suffered a heart attack at least one year prior and are at high risk of developing a further atherothrombotic event.

February 17, 2016 Off

Durvalumab granted BTD by FDA for cancer patients

By Dino Mustafić

AstraZeneca and MedImmune, its global biologics research and development arm, on Wednesday announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) for durvalumab (MEDI4736), an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1), for the treatment of patients with PD-L1 positive inoperable or metastatic urothelial bladder cancer whose tumour has progressed during or after one standard platinum-based regimen.

November 6, 2015 Off

AstraZeneca buys ZS Pharma

By Dino Mustafić

AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.